Are you Dr. Liljenquist?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 113 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3910 Washington Pkwy
Idaho Falls, ID 83404Phone+1 208-523-1122Fax+1 208-523-2582
Summary
- Dr. David Liljenquist, MD is an endocrinologist in Idaho Falls, Idaho. He is currently licensed to practice medicine in Idaho, Illinois, and Arizona. He is affiliated with Eastern Idaho Regional Medical Center and Mountain View Hospital.
Education & Training
University of ChicagoFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2005
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
George Washington University School of Medicine and Health SciencesClass of 2000
Certifications & Licensure
ID State Medical License 2005 - 2025
AZ State Medical License 2001 - 2005
IL State Medical License 2003 - 2005- National Board of Physicians and Surgeons Endocrinology Diabetes and Metabolism
- National Board of Physicians and Surgeons Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011, 2013
Clinical Trials
- Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Start of enrollment: 2011 Apr 01
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) Start of enrollment: 2014 Feb 01
- Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 69 citationsAccuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes.Shridhara Alva, Timothy L. Bailey, Ronald L. Brazg, Erwin S. Budiman, Kristin Castorino
Journal of Diabetes Science and Technology. 2020-09-19 - 35 citationsGlycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.Gregory P Forlenza, Laya Ekhlaspour, Linda A DiMeglio, Larry A Fox, Henry Rodriguez
Pediatric Diabetes. 2022-05-01 - 132 citationsSafety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.Gregory P. Forlenza, Orit Pinhas-Hamiel, David R Liljenquist, Dorothy I. Shulman, Timothy S. Bailey
Diabetes Technology & Therapeutics. 2019-01-08
Authored Content
- Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults with Type 1 DiabetesJune 2020
Professional Memberships
- Member
